AR053928A1 - Metodos reactivos para el tratamiento de trastornos inflamatorios - Google Patents

Metodos reactivos para el tratamiento de trastornos inflamatorios

Info

Publication number
AR053928A1
AR053928A1 ARP060102622A ARP060102622A AR053928A1 AR 053928 A1 AR053928 A1 AR 053928A1 AR P060102622 A ARP060102622 A AR P060102622A AR P060102622 A ARP060102622 A AR P060102622A AR 053928 A1 AR053928 A1 AR 053928A1
Authority
AR
Argentina
Prior art keywords
treatment
inflammatory disorders
reactive methods
bufexamac
corticosteroid
Prior art date
Application number
ARP060102622A
Other languages
English (en)
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37571103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053928(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of AR053928A1 publication Critical patent/AR053928A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente caracteriza un método para el tratamiento de un paciente con diagnostico o con riesgo de desarrollar un trastorno inmunoinflamatorio por administracion de bufexamac y un corticosteroide u otro compuesto al paciente. La presente también caracteriza una composicion farmacéutica que contiene bufexamac y un corticosteroide u otro compuesto para el tratamiento o la prevencion de un trastorno inmunoinflamatorio.
ARP060102622A 2005-06-17 2006-06-20 Metodos reactivos para el tratamiento de trastornos inflamatorios AR053928A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69195305P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
AR053928A1 true AR053928A1 (es) 2007-05-23

Family

ID=37571103

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102622A AR053928A1 (es) 2005-06-17 2006-06-20 Metodos reactivos para el tratamiento de trastornos inflamatorios

Country Status (8)

Country Link
US (1) US20060286177A1 (es)
EP (1) EP1896042A4 (es)
JP (1) JP2008543859A (es)
AR (1) AR053928A1 (es)
AU (1) AU2006259499A1 (es)
CA (1) CA2612244A1 (es)
TW (1) TW200740441A (es)
WO (1) WO2006138372A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008138123A1 (en) * 2007-05-09 2008-11-20 Thomas David Y Screening assay to identify correctors of protein trafficking defects
US20090111782A1 (en) * 2007-10-16 2009-04-30 Ghent University Composition and methods relating to glucocorticoid receptor-alpha and peroxisome proliferator-activated receptors
US20100240627A1 (en) * 2007-10-16 2010-09-23 Universiteit Gent Composition and methods relating to glucocorticoid receptor-alpha and peroxisome proliferator-activated receptors
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
CN106104764B (zh) * 2014-03-12 2019-12-10 嘉柏微电子材料股份公司 用于钨材料的化学机械抛光的组合物及方法
CN104958754B (zh) * 2015-06-12 2019-04-23 惠州市九惠制药股份有限公司 一种治疗红斑狼疮或银屑病的环孢菌素乳膏及其制备方法和应用
SI3310389T1 (sl) * 2015-06-18 2020-11-30 Bausch Health Ireland Limited Topični sestavki, ki obsegajo kortikosteroid in retinoid za zdravljenje psoriaze
TR201803213A2 (tr) * 2018-03-06 2018-04-24 Tambay Taskin Psori̇asi̇s tedavi̇si̇ i̇çi̇n pi̇mekroli̇mus, klobetazol ve kalsi̇potri̇ol i̇çeren topi̇kal farmasöti̇k formülasyonlar
CN112920168B (zh) * 2021-01-28 2021-11-23 浙江省疾病预防控制中心 一种他匹莫德及其衍生物或其药学上可接受的盐的新用途与结核分枝杆菌抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514667A (en) * 1990-11-05 1996-05-07 Arthropharm Pty. Limited Method for topical treatment of herpes infections
WO1994013257A1 (en) * 1992-12-16 1994-06-23 Creative Products Resource Associates, Ltd. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors

Also Published As

Publication number Publication date
EP1896042A4 (en) 2008-09-17
JP2008543859A (ja) 2008-12-04
WO2006138372A3 (en) 2007-03-29
CA2612244A1 (en) 2006-12-28
WO2006138372A2 (en) 2006-12-28
EP1896042A2 (en) 2008-03-12
AU2006259499A1 (en) 2006-12-28
US20060286177A1 (en) 2006-12-21
TW200740441A (en) 2007-11-01

Similar Documents

Publication Publication Date Title
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112014010228A2 (pt) inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112014008036A2 (pt) tratamento de rinite
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
BR112014027884A2 (pt) combinações farmacêuticas para tratamento de distúrbios metabólicos
MX2009011900A (es) Curacion de herida diabetica.
MX2009005798A (es) Recuperacion de apoplejia.
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
BRPI0416591A (pt) métodos e reagentes para o tratamento de distúrbios inflamatórios

Legal Events

Date Code Title Description
FB Suspension of granting procedure